{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:49:52Z","timestamp":1781063392676,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Gutenberg-Universit\u00e4t Mainz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Der systemische Lupus erythematodes (SLE) ist eine klinisch heterogen verlaufende Autoimmunerkrankung, die mit hohem Leid f\u00fcr die Betroffenen sowie hohen sozio\u00f6konomischen Kosten verbunden ist. Eine fr\u00fche Diagnosestellung und eine ad\u00e4quate medizinische Versorgung sind essenziell f\u00fcr einen milden Krankheitsverlauf. Es fehlen jedoch aktuelle Zahlen und Daten \u00fcber die Versorgungssituation der Erkrankten in der Fl\u00e4che.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodik<\/jats:title>\n                <jats:p>Es wurden insgesamt 1546 Haus\u00e4rzte, Rheumatologen, Neurologen, Nephrologen und Dermatologen in Rheinland-Pfalz und dem Saarland per Fax oder Mail mithilfe eines Fragebogens bez\u00fcglich Epidemiologie, Symptomatik, Therapie und Therapieerfolg befragt. Zus\u00e4tzlich gab es die M\u00f6glichkeit, Verbesserungsvorschl\u00e4ge zu unterbreiten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>F\u00fcnf von sechs der r\u00fcckgemeldeten 635 SLE-Patienten sind weiblich. Die h\u00e4ufigsten Hauptsymptome waren Arthralgien, Fatigue, Myalgien und Hautver\u00e4nderungen. Von den Patienten erhielten 68\u202f% Antimalariamittel (AMM), w\u00e4hrend 46\u202f% mit Glukokortikoiden (GC) und 50\u202f% mit einem Immunsuppressivum (IS), v.\u202fa. Methotrexat (MTX), behandelt wurden. An Komorbidit\u00e4ten litten die Patienten vor allem unter kardiovaskul\u00e4ren Erkrankungen, dem Fibromyalgiesyndrom und Depressionen. Rheumatologen beschrieben zudem h\u00e4ufig An\u00e4mien, Diabetes mellitus und Osteoporose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Verglichen mit den Empfehlungen der Leitlinien fiel insbesondere bei nicht rheumatologisch betreuten Patienten die geringe Quote an AMM in der Therapie auf (35\u202f% im Mittel im Vergleich zu 81\u202f% bei Rheumatologen). Auch (dauerhaft) hohe GC-Dosen entsprechen nicht den Empfehlungen der Literatur. Im Freitextfeld wurden vor allem mehr niedergelassene Rheumatologen und eine schnellere Terminvergabe sowie eine bessere Kommunikation und Vernetzung gew\u00fcnscht. Zudem wurde h\u00e4ufig der Wunsch nach mehr Fortbildung und Aufkl\u00e4rung ge\u00e4u\u00dfert.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00393-024-01491-1","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T18:01:57Z","timestamp":1710957717000},"page":"770-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Versorgungssituation des Systemischen Lupus Erythematodes in Rheinland-Pfalz und dem Saarland","Current patient care of systematic lupus erythematosus in Rhineland-Palatinate and Saarland"],"prefix":"10.1007","volume":"83","author":[{"given":"Ciaran","family":"Alberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Triantafyllias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"1491_CR1","doi-asserted-by":"crossref","unstructured":"Albrecht K, Binder S, Minden K et\u00a0al (2023) Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. Z\u00a0Rheumatol","DOI":"10.1007\/s00393-022-01302-5"},{"key":"1491_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00393-019-0680-1","volume":"78","author":"K Albrecht","year":"2019","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Zink\u00a0A (2019) Long-term trends in rheumatology care : achievements and deficits in 25\u00a0years of the German national rheumatology database. Z\u00a0Rheumatol 78:65\u201372","journal-title":"Z Rheumatol"},{"key":"1491_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00393-020-00933-w","volume":"80","author":"M Aringer","year":"2021","unstructured":"Aringer\u00a0M, Baerwald\u00a0C, Bergner\u00a0R et\u00a0al (2021) Rheumatology in German MD curricula. Z\u00a0Rheumatol 80:2\u20138","journal-title":"Z Rheumatol"},{"key":"1491_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0961203314540352","volume":"23","author":"R Brinks","year":"2014","unstructured":"Brinks\u00a0R, Fischer-Betz\u00a0R, Sander\u00a0O et\u00a0al (2014) Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. Lupus 23:1407\u20131411","journal-title":"Lupus"},{"key":"1491_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00393-011-0758-x","volume":"70","author":"G Chehab","year":"2011","unstructured":"Chehab\u00a0G, Fischer-Betz\u00a0R, Schneider\u00a0M (2011) Entwicklung von Mortalit\u00e4t und Morbidit\u00e4t beim systemischen Lupus erythematodes. Z\u00a0Rheumatol 70:480\u2013485","journal-title":"Z Rheumatol"},{"key":"1491_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1177\/0961203310385552","volume":"20","author":"GM Daleboudt","year":"2011","unstructured":"Daleboudt\u00a0GM, Broadbent\u00a0E, Berger\u00a0SP et\u00a0al (2011) Illness perceptions in patients with systemic lupus erythematosus and proliferative lupus nephritis. Lupus 20:290\u2013298","journal-title":"Lupus"},{"key":"1491_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3200\/BMED.35.1.5-13","volume":"35","author":"S Danoff-Burg","year":"2009","unstructured":"Danoff-Burg\u00a0S, Friedberg\u00a0F (2009) Unmet needs of patients with systemic lupus erythematosus. Behav Med 35:5\u201313","journal-title":"Behav Med"},{"key":"1491_CR8","volume-title":"Daten der Kerndokumentation der Regionalen Kooperativen Rheumazentren 2018","author":"DGRh","year":"2018","unstructured":"DGRh (2018) Daten der Kerndokumentation der Regionalen Kooperativen Rheumazentren 2018"},{"key":"1491_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.autrev.2010.08.014","volume":"10","author":"A Doria","year":"2010","unstructured":"Doria\u00a0A, Zen\u00a0M, Canova\u00a0M et\u00a0al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10:55\u201360","journal-title":"Autoimmun Rev"},{"key":"1491_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Alunno\u00a0A et\u00a0al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78:736\u2013745","journal-title":"Ann Rheum Dis"},{"key":"1491_CR11","doi-asserted-by":"crossref","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et\u00a0al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis","DOI":"10.1136\/ard-2024-226636"},{"key":"1491_CR12","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3899\/jrheum.120537","volume":"39","author":"R Fischer-Betz","year":"2012","unstructured":"Fischer-Betz\u00a0R, Chehab\u00a0G, Sander\u00a0O et\u00a0al (2012) Renal outcome in patients with lupus nephritis using a\u00a0steroid-free regimen of monthly intravenous cyclophosphamide: a\u00a0prospective observational study. J\u00a0Rheumatol 39:2111\u20132117","journal-title":"J Rheumatol"},{"issue":"584","key":"1491_CR13","first-page":"586","volume":"68","author":"R Fischer-Betz","year":"2009","unstructured":"Fischer-Betz\u00a0R, Schneider\u00a0M (2009) Antimalarials. A\u00a0treatment option for every lupus patient!? Z\u00a0Rheumatol 68(584):586\u2013590","journal-title":"Z Rheumatol"},{"key":"1491_CR14","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1007\/s00393-013-1193-y","volume":"72","author":"R Fischer-Betz","year":"2013","unstructured":"Fischer-Betz\u00a0R, Schneider\u00a0M (2013) Early lupus erythematosus. Z\u00a0Rheumatol 72:948\u2013953","journal-title":"Z Rheumatol"},{"key":"1491_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00393-005-0644-5","volume":"64","author":"R Fischer-Betz","year":"2005","unstructured":"Fischer-Betz\u00a0R, Wessel\u00a0E, Richter\u00a0J et\u00a0al (2005) Lupus in Germany: analysis within the German lupus self-help organization (LULA). Z\u00a0Rheumatol 64:111\u2013122","journal-title":"Z Rheumatol"},{"key":"1491_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1191\/096120398678919813","volume":"7","author":"PR Fortin","year":"1998","unstructured":"Fortin\u00a0PR, Abrahamowicz\u00a0M, Neville\u00a0C et\u00a0al (1998) Impact of disease activity and cumulative damage on the health of lupus patients. Lupus 7:101\u2013107","journal-title":"Lupus"},{"key":"1491_CR17","volume-title":"Duale Reihe Innere Medizin","author":"A Keikawus","year":"2018","unstructured":"Keikawus\u00a0A, Baenkle\u00a0H\u2011W, Biebe\u00a0C et\u00a0al (2018) Duale Reihe Innere Medizin. Georg Thieme Verlag KG, Stuttgart, New York"},{"key":"1491_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0961203319896626","volume":"29","author":"A Kernder","year":"2020","unstructured":"Kernder\u00a0A, Richter\u00a0JG, Fischer-Betz\u00a0R et\u00a0al (2020) Quality of care predicts outcome in systemic lupus erythematosus: a\u00a0cross-sectional analysis of a\u00a0German long-term study (LuLa cohort). Lupus 29:136\u2013143","journal-title":"Lupus"},{"key":"1491_CR19","first-page":"423","volume":"2015","author":"AB Kuhn","year":"2015","unstructured":"Kuhn\u00a0AB, Gisela, Anders\u00a0H\u2011J, Herzer\u00a0P, Tenbrock\u00a0K, Schneider\u00a0M (2015) Diagnostik und Therapie des systemischen Lupus erythematodes. Dtsch \u00c4rztebl Int 2015:423\u2013432","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"Suppl 4","key":"1491_CR20","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1186\/ar3919","volume":"14","author":"A Lateef","year":"2012","unstructured":"Lateef\u00a0A, Petri\u00a0M (2012) Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 14(Suppl 4):S4","journal-title":"Arthritis Res Ther"},{"key":"1491_CR21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00393-007-0250-9","volume":"67","author":"W Mau","year":"2008","unstructured":"Mau\u00a0W, Beyer\u00a0W, Ehlebracht-Konig\u00a0I et\u00a0al (2008) Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany. Z\u00a0Rheumatol 67:157\u2013164","journal-title":"Z Rheumatol"},{"key":"1491_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s00393-019-0633-8","volume":"78","author":"J Mucke","year":"2019","unstructured":"Mucke\u00a0J, Fischer-Betz\u00a0R, Schneider\u00a0M (2019) State of the art: systemic lupus erythematosus. Z\u00a0Rheumatol 78:500\u2013510","journal-title":"Z Rheumatol"},{"key":"1491_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40744-020-00195-7","volume":"7","author":"E Nyman","year":"2020","unstructured":"Nyman\u00a0E, Vaughan\u00a0T, Desta\u00a0B et\u00a0al (2020) Characteristics and symptom severity of patients reporting systemic lupus erythematosus in the patients like me online health community: a\u00a0retrospective observational study. Rheumatol Ther 7:201\u2013213","journal-title":"Rheumatol Ther"},{"key":"1491_CR24","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40258-014-0085-x","volume":"12","author":"A Oglesby","year":"2014","unstructured":"Oglesby\u00a0A, Korves\u00a0C, Laliberte\u00a0F et\u00a0al (2014) Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy 12:179\u2013190","journal-title":"Appl Health Econ Health Policy"},{"issue":"578","key":"1491_CR25","first-page":"580","volume":"68","author":"M Schneider","year":"2009","unstructured":"Schneider\u00a0M (2009) EULAR recommendations for the management of systemic lupus erythematosus. Z\u00a0Rheumatol 68(578):580\u2013573","journal-title":"Z Rheumatol"},{"key":"1491_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40744-021-00277-0","volume":"8","author":"A Schwarting","year":"2021","unstructured":"Schwarting\u00a0A, Friedel\u00a0H, Garal-Pantaler\u00a0E et\u00a0al (2021) The burden of systemic lupus erythematosus in Germany: incidence, prevalence, and healthcare resource utilization. Rheumatol Ther 8:375\u2013393","journal-title":"Rheumatol Ther"},{"key":"1491_CR27","doi-asserted-by":"publisher","first-page":"rkaa006","DOI":"10.1093\/rap\/rkaa006","volume":"4","author":"M Sloan","year":"2020","unstructured":"Sloan\u00a0M, Harwood\u00a0R, Sutton\u00a0S et\u00a0al (2020) Medically explained symptoms: a\u00a0mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases. Rheumatol Adv Pract 4:rkaa6","journal-title":"Rheumatol Adv Pract"},{"key":"1491_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","volume":"12","author":"GC Tsokos","year":"2016","unstructured":"Tsokos\u00a0GC, Lo\u00a0MS, Costa Reis\u00a0P et\u00a0al (2016) New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12:716\u2013730","journal-title":"Nat Rev Rheumatol"},{"key":"1491_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00393-017-0297-1","volume":"76","author":"A Zink","year":"2017","unstructured":"Zink\u00a0A, Braun\u00a0J, Gromnica-Ihle\u00a0E et\u00a0al (2017) Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology\u2014update 2016. Z\u00a0Rheumatol 76:195\u2013207","journal-title":"Z Rheumatol"},{"key":"1491_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00393-009-0522-7","volume":"69","author":"A Zink","year":"2010","unstructured":"Zink\u00a0A, Huscher\u00a0D, Schneider\u00a0M (2010) How closely does rheumatology treatment follow the guidelines?: ambition and reality. Z\u00a0Rheumatol 69:318\u2013326","journal-title":"Z Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01491-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01491-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01491-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:03:08Z","timestamp":1730368988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01491-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1491"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01491-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"4 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Alberti, M.\u00a0Dreher, K.\u00a0Triantafyllias und A.\u00a0Schwarting geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}